Boston Scientific upgraded to buy at Needham on new products, potential M&A target (BSX)
seekingalpha.com
finance
2022-05-27 15:31:11

Sundry Photography/iStock Editorial via Getty Images Needham has upgraded Boston Scientific (NYSE:BSX) to buy from hold citing new products in its portfolio and the possibility it could be an acquisition target. The firm has a $48 price target (~20% upside based on Thursday's close). Analyst Mike Matson wrote that even with a slowdown in sales of its WATCHMAN left atrial appendage closure device, Boston Scientific (BSX) can still have single digit growth due to several new products in its portfolio.
